Sangui Biotech International (SGBI) 10-Q/A 7 May 21 2021 Q3 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2021	May 07, 2021
Details
Registrant CIK	0001104280
Fiscal Year End	--06-30
Registrant Name	SANGUI BIOTECH INTERNATIONAL INC
SEC Form	10-Q/A
Period End date	Mar. 31, 2021
Tax Identification Number (TIN)	84-1330732
Number of common stock shares outstanding		206,901,842
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Amendment Description	The purpose of this Amendment No. 1 to the Periodic Report of Sangui Biotech International, Inc. (the “Company”) on Form 10-Q for the fiscal period ended March 31, 2021, filed with the Securities and Exchange Commission on May 7, 2021 (the “Form 10-Q”) is to correct the information in Part II Item 2. The Company in its Form 10-Q filing indicated that there had been no unregistered sales of its equity securities, while in fact there had been a sale of stock subsequent to the period covered by the report. This Amendment No. 1 corrects this section to reflect the recent issuance. No changes are hereby made to the registrant’s financial statements.
Document Quarterly Report	true
Entity File Number	0-21271
Entity Address, State or Province	CO
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	Bleichenbrücke 9
Entity Address, Postal Zip Code	20354
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Country Region	49
City Area Code	40
Local Phone Number	46093120
Document Transition Report	false
Amendment Flag	true
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Jun. 30, 2020
CURRENT ASSETS
Cash	$ 11,620	$ 15,282
Prepaid expenses and other assets	14,995	13,361
Tax refunds receivable	737	3,317
Accounts receivable, net	25,152	9,858
Note receivable, related party	2,066	6,878
Total Current Assets	54,570	48,696
Property and Equipment, Net	1,405	1,922
Operating lease right-of-use asset	70,349	74,710
TOTAL ASSETS	126,324	125,328
LIABILITIES
Accounts payable and accrued expenses	135,140	119,246
Accrued interest - related party	57,343	42,359
Notes payable - related party	745,962	618,568
Current portion of operating lease liability	13,743	11,312
Total Current Liabilities	952,188	791,485
Operating lease liability, net of current portion	57,390	63,721
Total Liabilities	1,009,578	855,206
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 203,355,598 and 203,355,598 shares issued and 203,301,842 and 203,301,842 shares outstanding respectively	33,027,676	33,027,676
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	90,454	91,907
Accumulated deficit	(37,845,291)	(37,696,425)
Total Sangui Biotech International, Inc's stockholders' defict	(233,220)	(82,901)
Non-controlling interest	(650,034)	(646,977)
Total Stockholders' Deficit	(883,254)	(729,878)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 126,324	$ 125,328

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - shares	Mar. 31, 2021	Jun. 30, 2020
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	203,355,598	203,355,598
Common Stock, Shares, Outstanding	203,301,842	203,301,842

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
REVENUES
License revenues	$ 21,182	$ 9,211	$ 51,754	$ 21,176
GROSS MARGIN	21,182	9,211	51,754	21,176
OPERATING EXPENSES
Research and development	2,060	1,535	6,482	6,421
Professional fees	32,911	35,521	117,750	114,939
General and administrative	14,330	8,590	37,951	28,682
Depreciation and amortization	206	1,020	610	1,020
Total Operating Expenses	49,507	46,666	162,793	151,062
OPERATING LOSS	(28,325)	(37,455)	(111,039)	(129,886)
OTHER INCOME (EXPENSE)
Loss on out of court settlement	0	0	0	(6,714)
Gain (Loss) on foreign exchange	32,167	12,838	(27,611)	19,547
Interest expense	(4,580)	(3,667)	(13,273)	(10,357)
Total other income (expense)	27,587	9,171	(40,884)	2,476
LOSS BEFORE INCOME TAXES AND NON-CONTROLLING INTEREST	(738)	(28,284)	(151,923)	(127,410)
Provision for income taxes	0	0	0	0
NET LOSS BEFORE NON-CONTROLLING INTEREST	(738)	(28,284)	(151,923)	(127,410)
Less: Net loss attributable to non-controlling interest	648	1,588	3,057	3,982
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(90)	(26,696)	(148,866)	(123,428)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(287)	(1,894)	(1,453)	(1,129)
COMPREHENSIVE LOSS	$ (1,025)	$ (30,178)	$ (153,376)	$ (128,539)
BASIC AND DILUTED LOSS PER SHARE	$ 0	$ 0	$ 0	$ 0
NUMBER OF SHARES OUTSTANDING	203,355,598	202,308,054	203,355,598	201,313,316

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Treasury Stock	AOCI Including Portion Attributable to Noncontrolling Interest	Noncontrolling Interest	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2019	$ 32,967,499	$ 4,513,328	$ (19,387)	$ 91,447	$ (641,192)	$ (37,503,684)	$ (591,989)
Shares, Outstanding, Beginning Balance at Jun. 30, 2019	199,295,503
Currency translation adjustment	$ 0	0	0	(1,129)	0	0	(1,129)
Net loss	0	0	0	0	(3,982)	(123,428)	(127,410)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2020	$ 33,023,316	4,513,328	(19,387)	90,318	(645,174)	(37,627,112)	(664,711)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	202,783,598
Proceeds from common stock issued for cash	$ 11,055	0	0	0	0	0	11,055
Common stock issued for cash	1,250,000
Common stock issued for services	$ 44,762	0	0	0	0	0	44,762
Common stock issued for services	2,238,095
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2019	$ 33,012,261	4,513,328	(19,387)	92,212	(643,586)	(37,600,416)	(645,588)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	201,533,598
Currency translation adjustment	$ 0	0	0	(1,894)	0	0	(1,894)
Net loss	0	0	0	0	(1,588)	(26,696)	(28,284)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2020	$ 33,023,316	4,513,328	(19,387)	90,318	(645,174)	(37,627,112)	(664,711)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	202,783,598
Proceeds from common stock issued for cash	$ 11,055	0	0	0	0	0	11,055
Common stock issued for cash	1,250,000
Common stock issued out of court settlement	$ 0	0	0	0	0	0	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2020	$ 33,027,676	4,513,328	(19,387)	91,907	(646,977)	(37,696,425)	(729,878)
Shares, Outstanding, Beginning Balance at Jun. 30, 2020	203,355,598
Currency translation adjustment	$ 0	0	0	(1,453)	0	0	(1,453)
Net loss	0	0	0	0	(3,057)	(148,866)	(151,923)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2021	$ 33,027,676	4,513,328	(19,387)	90,454	(650,034)	(37,845,291)	(883,254)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	203,355,598
Proceeds from common stock issued for cash							0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2020	$ 33,027,676	4,513,328	(19,387)	90,741	(649,386)	(37,845,201)	(882,229)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	203,355,598
Currency translation adjustment	$ 0	0	0	(287)	0	0	(287)
Net loss	0	0	0	0	(648)	(90)	(738)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2021	$ 33,027,676	$ 4,513,328	$ (19,387)	$ 90,454	$ (650,034)	$ (37,845,291)	$ (883,254)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	203,355,598

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (151,923)	$ (127,410)
Adjustments to reconcile net loss to net cash
Depreciation and amortization	610	1,020
Common stock issued for out of court settlement	0	6,714
Foreign currency exchange transactions	27,611	(19,495)
Amortization of right to use asset	(16,009)	(7,898)
Changes in operating assets and liabilities
Trade accounts receivable	(15,518)	17,261
Prepaid expenses and other current assets	(5,193)	(3,387)
Tax refunds receivable	6,660	(6,021)
Accounts payable and accrued expenses	15,604	(9,091)
Related party advances	5,665	2,054
Related party accounts payable	11,852	10,202
Operating lease liability	16,463	7,898
Net Cash Used in Operating Activities	(104,178)	(128,153)
Net Cash Provided by (Used in) Investing Activities
Purchase of equipment	0	(3,102)
Net Cash Used in Investing Activities	0	(3,102)
Net Cash Provided by (Used in) Financing Activities
Proceeds from related party note payable	101,515	105,222
Proceeds from common stock issued for cash	0	11,055
Net Cash Provided by Financing Activities	101,515	116,277
EFFECTS OF EXCHANGE RATES ON CASH	(999)	(907)
NET CHANGES IN CASH	(3,662)	(15,885)
CASH AT BEGINNING OF PERIOD	15,282	27,453
CASH AT END OF PERIOD	11,620	11,568
NON - CASH INVESTING AND FINANCING ACTIVITIES
Right-of-use operating lease assets obtained in exchange for lease liabilities	0	81,936
Common Stock issued in settlement of liability	$ 0	$ 44,762

NOTE 1 - BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION	9 Months Ended
	Mar. 31, 2021
Notes
NOTE 1 - BASIS OF PRESENTATION	NOTE 1 - BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2020. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three- and nine-month period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2021. In December 2019, COVID-19 emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining of people who may have been exposed to the virus. At the present time, it is not clear how long this crisis will last and what extent it will take. The highest priority for the Company is the health of employees and business partners. The Company’s main product is affected by the restrictions currently in place around the world. The global restrictions drastically limit our sales activities. Therefore, the license revenue the Company anticipated is not, and for the foreseeable future, will not be received at the levels as planned. The Company is in close contact with its licensee who is responsible for all distribution. Both the Company and its licensee assume that the desired growth of sales will be resumed after the pandemic has been overcome and restrictions are lessened. Prior to the pandemic, the Company had essentially been financed through the sale of shares or by loans from related parties. These financing options are still available to the Company during the COVID-19 crisis.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2021
Notes
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its 90% owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Hamburg, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Sangui KG is a limited partnership that holds the license rights under the various agreements that the Company enters into from time to time. Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2021 and June 30, 2020 and our unaudited consolidated statements of operations for the three- month periods ended March 31, 2021 and 2020, were calculated as follows: as of March 31, 2021 0.851250 as of March 31, 2020 0.911235 July 1, 2020 through March 31, 2021 0.841351 July 1, 2019 through March 31, 2020 0.902936 The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,845,291 as of March 31, 2021. The Company incurred a net loss before non-controlling interest of $151,923 for the nine-months ended March 31, 2021 and used cash in operating activities of $104,178 during the same nine-months ended March 31, 2021. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts. Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred. Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied. Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2021, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive. Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit). Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 3 - COMMITMENTS AND CONTIN

NOTE 3 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Mar. 31, 2021
Notes
NOTE 3 - COMMITMENTS AND CONTINGENCIES	NOTE 3 - COMMITMENTS AND CONTINGENCIES Litigation The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a material effect on the Company's financial position or results of operations. At the time of reporting, no litigation is pending. Indemnities and Guarantees During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet. Leases The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2021: Minimum Lease Payments Under Operating Leases Office Automotive Total Year ending June 30, 2021 $ 3,351 $ 1,573 $ 4,924 2022 13,514 - 13,514 2023 13,758 - 13,758 2024 14,005 - 14,005 Thereafter 28,772 - 28,772 Total Operating Lease Obligations $ 73,400 $ 1,573 $ 74,973 Less: Amount representing imputed interest $ (3,836) $ (4) $ (3,840) Present Value of minimum lease payments $ 69,564 $ 1,569 $ 71,133 Weighted average discount rate 2% Weighted average remaining term 5.14 years License Agreement Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH and Sangui KG, respectively, and a former contractor, Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG).

NOTE 4 - RELATED PARTY TRANSACT

NOTE 4 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Mar. 31, 2021
Notes
NOTE 4 - RELATED PARTY TRANSACTIONS	NOTE 4 – DEBT Notes Payable Related Parties As of March 31, 2021, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 117,474 5% 34,625 June 30, 2020 December 12, 2017 25,000 29,369 2% 1,939 on demand January 19, 2018 25,000 29,369 2% 1,878 on demand March 13, 2018 25,000 29,369 2% 1,793 on demand July 16, 2018 25,000 29,369 2% 1,592 on demand September 10, 2018 25,000 29,369 2% 1,501 on demand October 04, 2018 25,000 29,369 2% 1,463 on demand December 27, 2018 25,000 29,369 2% 1,328 on demand January 21, 2019 15,000 17,621 2% 772 on demand February 26, 2019 25,000 29,369 2% 1,229 on demand March 20, 2019 25,000 29,369 2% 1,194 on demand April 08, 2019 20,000 23,495 2% 931 on demand May 09, 2019 30,000 35,242 2% 1,336 on demand June 21, 2019 30,000 35,242 2% 1,253 on demand September 17, 2019 20,000 23,495 2% 722 on demand October 04, 2019 20,000 23,495 2% 700 on demand October 30, 2019 20,000 23,495 2% 667 on demand January 08, 2020 10,000 11,747 2% 288 on demand February 20, 2020 10,000 11,747 2% 261 on demand March 06, 2020 15,000 17,621 2% 377 on demand April 01, 2020 10,000 11,747 2% 234 on demand May 05, 2020 15,000 17,621 2% 319 on demand June 10, 2020 10,000 11,747 2% 189 on demand July 27, 2020 10,000 11,747 2% 159 on demand September 07, 2020 10,000 11,747 2% 132 on demand September 21, 2020 10,000 11,747 2% 123 on demand October 09, 2020 15,000 17,621 2% 167 on demand December 03, 2020 10,000 11,747 2% 76 on demand January 05, 2021 10,000 11,747 2% 55 on demand Februay 11, 2021 10,000 11,747 2% 31 on demand March 17, 2021 10,000 11,747 2% 9 on demand Total 635,000 745,962 57,343 On July 27, 2020, September 07, 2020, September 21, 2020, October 09,2020, December 03,2020, January 05, 2021, February 11, 2021 and on March 17, 2021 a Company Director advanced amounts totaling 85,000 Euros ($101,515 as of March 31, 2021) to the Company. The loans are due on demand, accrue interest annually at 2% and are unsecured. As of March 31, 2021, all notes issued have total interest accrued of $57,343. Interest expense for the nine-month period ended March 31, 2021 and 2020 was $13,273 and $10,357, respectively.

NOTE 5 - CAPITAL STOCK

NOTE 5 - CAPITAL STOCK	9 Months Ended
	Mar. 31, 2021
Notes
NOTE 5 - CAPITAL STOCK	NOTE 5 – STOCKHOLDERS’ DEFICT Preferred Stock Common Stock Treasury Stock

NOTE 6 - SUBSEQUENT EVENTS

NOTE 6 - SUBSEQUENT EVENTS	9 Months Ended
	Mar. 31, 2021
Notes
NOTE 6 - SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS Subsequent to March 31, 2021, the Company sold 3,600,000 shares of its common stock for approximately $58,737 in cash proceeds to one individual at price of approximately $0.0163 per share. In accordance with ASC 855-10, the Company’s management has reviewed all material events and there are no additional material subsequent events to report.

NOTE 2 - SUMMARY OF SIGNIFICA_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Consolidation (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Consolidation	Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

NOTE 2 - SUMMARY OF SIGNIFICA_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Foreign Currency Translation	Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2021 and June 30, 2020 and our unaudited consolidated statements of operations for the three- month periods ended March 31, 2021 and 2020, were calculated as follows: as of March 31, 2021 0.851250 as of March 31, 2020 0.911235 July 1, 2020 through March 31, 2021 0.841351 July 1, 2019 through March 31, 2020 0.902936 The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income.

NOTE 2 - SUMMARY OF SIGNIFICA_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,845,291 as of March 31, 2021. The Company incurred a net loss before non-controlling interest of $151,923 for the nine-months ended March 31, 2021 and used cash in operating activities of $104,178 during the same nine-months ended March 31, 2021. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 - SUMMARY OF SIGNIFICA_5

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.

NOTE 2 - SUMMARY OF SIGNIFICA_6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Research and Development	Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.

NOTE 2 - SUMMARY OF SIGNIFICA_7

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied.

NOTE 2 - SUMMARY OF SIGNIFICA_8

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basic and Diluted Loss per Common Share (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Basic and Diluted Loss per Common Share	Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2021, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.

NOTE 2 - SUMMARY OF SIGNIFICA_9

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Comprehensive Loss (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Comprehensive Loss	Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).

NOTE 2 - SUMMARY OF SIGNIFIC_10

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segments of an Enterprise and Related Information (Policies)	9 Months Ended
	Mar. 31, 2021
Policies
Segments of an Enterprise and Related Information	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 2 - SUMMARY OF SIGNIFIC_11

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Tables)	9 Months Ended
	Mar. 31, 2021
Tables/Schedules
Schedule of Foreign currency rates	as of March 31, 2021 0.851250 as of March 31, 2020 0.911235 July 1, 2020 through March 31, 2021 0.841351 July 1, 2019 through March 31, 2020 0.902936

NOTE 3 - COMMITMENTS AND CONT_2

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Tables)	9 Months Ended
	Mar. 31, 2021
Tables/Schedules
Minimum Lease Payments Under Operating Leases	The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2021: Minimum Lease Payments Under Operating Leases Office Automotive Total Year ending June 30, 2021 $ 3,351 $ 1,573 $ 4,924 2022 13,514 - 13,514 2023 13,758 - 13,758 2024 14,005 - 14,005 Thereafter 28,772 - 28,772 Total Operating Lease Obligations $ 73,400 $ 1,573 $ 74,973 Less: Amount representing imputed interest $ (3,836) $ (4) $ (3,840) Present Value of minimum lease payments $ 69,564 $ 1,569 $ 71,133 Weighted average discount rate 2% Weighted average remaining term 5.14 years

NOTE 4 - RELATED PARTY TRANSA_2

NOTE 4 - RELATED PARTY TRANSACTIONS: Notes Payable Related Parties (Tables)	9 Months Ended
	Mar. 31, 2021
Tables/Schedules
Notes Payable Related Parties	As of March 31, 2021, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 117,474 5% 34,625 June 30, 2020 December 12, 2017 25,000 29,369 2% 1,939 on demand January 19, 2018 25,000 29,369 2% 1,878 on demand March 13, 2018 25,000 29,369 2% 1,793 on demand July 16, 2018 25,000 29,369 2% 1,592 on demand September 10, 2018 25,000 29,369 2% 1,501 on demand October 04, 2018 25,000 29,369 2% 1,463 on demand December 27, 2018 25,000 29,369 2% 1,328 on demand January 21, 2019 15,000 17,621 2% 772 on demand February 26, 2019 25,000 29,369 2% 1,229 on demand March 20, 2019 25,000 29,369 2% 1,194 on demand April 08, 2019 20,000 23,495 2% 931 on demand May 09, 2019 30,000 35,242 2% 1,336 on demand June 21, 2019 30,000 35,242 2% 1,253 on demand September 17, 2019 20,000 23,495 2% 722 on demand October 04, 2019 20,000 23,495 2% 700 on demand October 30, 2019 20,000 23,495 2% 667 on demand January 08, 2020 10,000 11,747 2% 288 on demand February 20, 2020 10,000 11,747 2% 261 on demand March 06, 2020 15,000 17,621 2% 377 on demand April 01, 2020 10,000 11,747 2% 234 on demand May 05, 2020 15,000 17,621 2% 319 on demand June 10, 2020 10,000 11,747 2% 189 on demand July 27, 2020 10,000 11,747 2% 159 on demand September 07, 2020 10,000 11,747 2% 132 on demand September 21, 2020 10,000 11,747 2% 123 on demand October 09, 2020 15,000 17,621 2% 167 on demand December 03, 2020 10,000 11,747 2% 76 on demand January 05, 2021 10,000 11,747 2% 55 on demand Februay 11, 2021 10,000 11,747 2% 31 on demand March 17, 2021 10,000 11,747 2% 9 on demand Total 635,000 745,962 57,343

NOTE 2 - SUMMARY OF SIGNIFIC_12

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2021
Sangui BioTech GmbH
Equity Method Investment, Ownership Percentage	90.00%

NOTE 2 - SUMMARY OF SIGNIFIC_13

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Year End Rates
Foreign Currency Exchange Rate, Translation	0.851250	0.911235
Average Period Rates
ForeignCurrencyExchangeRateTranslation	0.841351	0.902936

NOTE 2 - SUMMARY OF SIGNIFIC_14

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Details
Accumulated deficit	$ 37,845,291		$ 37,845,291		$ 37,696,425
NET LOSS BEFORE NON-CONTROLLING INTEREST	$ 738	$ 28,284	151,923	$ 127,410
Net Cash Used in Operating Activities			$ 104,178	$ 128,153

NOTE 3 - COMMITMENTS AND CONT_3

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Details)	9 Months Ended
	Mar. 31, 2021USD ($)
2021	$ 4,924
2022	13,514
2023	13,758
2024	14,005
Thereafter	28,772
Total Operating Lease Obligations	74,973
Less: Amount representing imputed interest	(3,840)
Present Value of minimum lease payments	71,133
Office
2021	3,351
2022	13,514
2023	13,758
2024	14,005
Thereafter	28,772
Total Operating Lease Obligations	73,400
Less: Amount representing imputed interest	(3,836)
Present Value of minimum lease payments	69,564
Automobile
2021	1,573
2022	0
2023	0
2024	0
Thereafter	0
Total Operating Lease Obligations	1,573
Less: Amount representing imputed interest	(4)
Present Value of minimum lease payments	$ 1,569

NOTE 4 - RELATED PARTY TRANSA_3

NOTE 4 - RELATED PARTY TRANSACTIONS: Notes Payable Related Parties (Details) - USD ($)	Mar. 31, 2021	Mar. 17, 2021	Feb. 11, 2021	Jan. 05, 2021	Dec. 03, 2020	Oct. 09, 2020	Sep. 21, 2020	Sep. 07, 2020	Jul. 27, 2020	Jun. 10, 2020	May 05, 2020	Apr. 01, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Interest rate		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Due		on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	June 30, 2020
Director
Interest rate	2.00%
Director | Euro Member Countries, Euro
Loan amount in EURO	$ 635,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 15,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 15,000	$ 10,000	$ 15,000	$ 10,000	$ 10,000	$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 20,000	$ 25,000	$ 25,000	$ 15,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 100,000
Director | United States dollar (next day) (funds code)
Loan amount converted into USD	745,962	11,747	11,747	11,747	11,747	17,621	11,747	11,747	11,747	11,747	17,621	11,747	17,621	11,747	11,747	23,495	23,495	23,495	35,242	35,242	23,495	29,369	29,369	17,621	29,369	29,369	29,369	29,369	29,369	29,369	29,369	117,474
Interest in USD	$ 57,343	$ 9	$ 31	$ 55	$ 76	$ 167	$ 123	$ 132	$ 159	$ 189	$ 319	$ 234	$ 377	$ 261	$ 288	$ 667	$ 700	$ 722	$ 1,253	$ 1,336	$ 931	$ 1,194	$ 1,229	$ 772	$ 1,328	$ 1,463	$ 1,501	$ 1,592	$ 1,793	$ 1,878	$ 1,939	$ 34,625

NOTE 4 - RELATED PARTY TRANSA_4

NOTE 4 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 17, 2021	Feb. 11, 2021	Jan. 05, 2021	Dec. 03, 2020	Oct. 09, 2020	Sep. 21, 2020	Sep. 07, 2020	Jul. 27, 2020	Jun. 30, 2020	Jun. 10, 2020	May 05, 2020	Apr. 01, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Accrued interest - related party	$ 57,343										$ 42,359
Interest rate			2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Interest Expense	$ 13,273	$ 10,357
Director
Interest rate	2.00%
Director | Principal
Accrued interest - related party	$ 101,515
Director | Interest
Accrued interest - related party	$ 57,343

NOTE 5 - CAPITAL STOCK (Details

NOTE 5 - CAPITAL STOCK (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	203,355,598	203,355,598
Common Stock, Shares, Outstanding	203,301,842	203,301,842
Treasury Stock, Common, Shares	53,756
Treasury Stock, Value	$ 19,387